Lineage Cell Therapeutics, Inc. 8-K

What Happened

• Lineage Cell Therapeutics, Inc. (LCTX) filed an 8-K on June 12, 2026 reporting results from its Annual Meeting held June 10, 2026 and disclosing that it withdrew its CIRM Clinical Trial (CLIN2) award application on June 9, 2026.
• All seven board nominees were elected to serve until the 2027 annual meeting: Michael H. Mulroy; Dipti Amin; Deborah Andrews; Angus C. Russell; Neal C. Bradsher; Brian M. Culley; and Anula Jayasuriya. Broker non-votes totaled 73,917,854.
• Shareholders ratified Baker Tilly US, LLP as the company’s independent registered public accounting firm for fiscal 2026 and approved, on an advisory basis, executive compensation (say-on-pay).
• The company withdrew its CIRM grant application (to support OPC1 development for spinal cord injury) after receiving comments from CIRM; the withdrawal does not affect the ongoing DOSED study of OPC1.

Key Details

• Annual Meeting date: June 10, 2026; 8‑K filed June 12, 2026.
• Director election example vote totals: Michael H. Mulroy — 90,383,337 for / 1,201,448 withheld; Anula Jayasuriya — 90,549,317 for / 1,035,468 withheld. (All seven nominees were elected.)
• Auditor ratification: Baker Tilly US, LLP — 163,825,928 votes for; 659,670 against; 1,017,041 abstentions.
• Advisory approval of executive compensation: 88,328,168 for; 2,600,932 against; 655,685 abstentions; 73,917,854 broker non-votes.
• CIRM grant application withdrawn on June 9, 2026; company states withdrawal does not impact current/planned DOSED trial (subacute and chronic SCI participants).

Why It Matters

• Board continuity and auditor ratification remove near-term governance uncertainty and keep management’s strategic team intact through 2027, which investors often view as supportive for execution.
• The advisory say-on-pay passed, indicating shareholder support for executive compensation policy (non-binding).
• Withdrawing the CIRM grant application means Lineage will not receive that specific potential CIRM funding; however, the company states this does not change its active clinical program for OPC1 (DOSED). Investors should watch for future financing or grant updates and progress reports from the DOSED study for implications on funding and clinical milestones.